Reportlinker.com: Forecast Performance for Organon in the Ethical Pharmaceutical Sector

Business Wire, Nov 15, 2007

LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is available in its catalogue.

Organon: PharmaVitae Profile

To order that report:

www.reportlinker.com/p063020/PRBW-Organon-Profile.html

For more information, contact Nicolas by email nbo@reportlinker.com , or by phone +33 4 37 65 17 03.

Description

Introduction

This analysis examines the historical and forecast performance for Organon in the ethical pharmaceutical sector.

The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Organon's performance against key rivals in the ethical pharmaceutical sector.

Evaluate Organon's prospects out to 2012, following the recent $14.8 billion acquisition bid by US-based Big Pharma Schering-Plough.

Learn how Organon's innovative late-stage pipeline, from which six new products are set to launch, is central to the company's healthy outlook.

Table of content

CHAPTER 1 EXECUTIVE SUMMARY

Key findings

Historical and forecast ethical sales performance

Therapeutic strategy

Launch and expiry outlook

Externalization, geographic and molecule type strategies

Externalization strategy

Geographic strategy

Molecule type strategy

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

CHAPTER 2 CORPORATE HISTORY

Key findings

Background

Key corporate developments

Imminent IPO diverted following Schering-Plough's entry into the fray

M&A history

M&A strategy

Organon M&A

Current corporate structure

Current management team

CHAPTER 3 HISTORICAL PERFORMANCE

Key findings

Introduction

Revenue and growth rate analysis, 2001-06

Revenue and growth rate vs. peer set

Product analysis, 2001-06

Growth drivers

NuvaRing

Puregon

Growth resistors

Remeron

Livial

Operating revenue and cost analysis, 2001-06

Operating revenue/cost analysis

CHAPTER 4 FORECAST PERFORMANCE

Key findings

Introduction

Revenue and growth rate, 2006-12

Product analysis, 2006-12

Growth drivers

Asenapine

Sugammadex

Org 50081 (insomnia)

NuvaRing

Implanon

Growth resistors

Esmeron

Livial

Therapy area analysis, 2006-12

Central nervous system

Urology & sexual health

Therapy area focus

Launches and expiries analysis, 2006-12

Launch portfolio

Core portfolio

Expiry portfolio

Launch/core/expiry configuration

Externalization analysis, 2006-12

Geographic analysis, 2006-12

Molecule type analysis, 2006-12

CHAPTER 5 KEY PRODUCTS AND COMPETITORS

Key findings

Overview

Women's health

NuvaRing

CHAPTER 6 APPENDIX

IMS vs. company-reported data reconciliation

References

Abbreviations

Exchange rates

List of Tables

Table 1: Organon Biosciences Executive Committee

Table 2: Peer set overview

Table 3: Operating revenue/cost analysis ($m), 2001-06

Table 4: Operating cost ratio analysis (% of total revenues), 2001-06

Table 5: Product portfolio overview, sales ($m), 2006-12

Table 6: Therapy area overview, sales ($m), 2006-12

Table 7: Launch portfolio overview, sales ($m), 2006-12

Table 8: Core portfolio overview, sales ($m), 2006-12

Table 9: Expiry portfolio overview, sales ($m), 2006-12

Table 10: Externally developed portfolio ($m), 2006-12

Table 11: Molecule type overview, sales ($m), 2006-12

Table 12: Key products overview

Table 13: NuvaRing: overview

Table 14: NuvaRing: sales forecast ($m), 2006-12

Table 15: NuvaRing: news flow

Table 16: Organon's non-DTC marketing expenditure in 2006

Table 17: Top 10 contraceptive products in 2006 (7MM)

Table 18: Puregon/Follistim: overview

Table 19: Puregon/Follistim: sales forecast ($m), 2006-12

Table 20: Puregon/Follistim: news flow

Table 21: Implanon: overview

Table 22: Implanon: sales forecast ($m), 2006-12

Table 23: Implanon: news flow

Table 24: NOMAC/E2: overview

Table 25: NOMAC/E2: sales forecast ($m), 2006-12

Table 26: NOMAC/E2: news flow

Table 27: Org 32686: overview

Table 28: Org 32686: sales forecast ($m), 2006-12

Table 29: Org 32686: news flow

Table 30: Asenapine: overview

Table 31: Asenapine: sales forecast ($m), 2006-12

Table 32: Asenapine: news flow

Table 33: Sugammadex: overview

Table 34: Sugammadex: sales forecast ($m), 2006-12

Table 35: Sugammadex: news flow

Table 36: Remeron: overview

Table 37: Remeron: sales forecast ($m), 2006-12

Table 38: Remeron: news flow

Table 39: Org 50081 (insomnia): overview

Table 40: Org 50081 (insomnia): sales forecast ($m), 2006-12

Table 41: Org 50081 (insomnia): news flow

Table 42: Esmeron: overview

Table 43: Esmeron/Zemuron: sales forecast ($m), 2006-12

Table 44: Esmeron/Zemuron: news flow

Table 45: Organon's R&D pipeline (Phase I-registration)

Table 46: Exchange rates, 2006

More market research reports? Go to http://www.reportlinker.com

http://market-research.typepad.com/agricultural_chemicals/